Charles River Laboratories Reports Q3 2026 Results with Strong Organic Growth and Increased Guidance
Charles River Laboratories (CRL) reported third-quarter 2026 revenue of $982.7 million, a slight reported decline of 2.2% due to recent divestitures. However, the company demonstrated robust underlying performance with organic revenue growth of 4.7%, surpassing previous guidance. This strength was primarily driven by the Discovery and Safety Assessment (DSA) and Manufacturing segments, which saw organic growth of 5.9% and 7.4%, respectively. Profitability metrics showed significant improvement, with Non-GAAP EPS rising 27.2% year-over-year to $3.09. The company also raised its full-year organic revenue guidance to at least 1.5% growth. While the Research Model Solutions (RMS) segment faced headwinds from government funding uncertainty, the strong backlog in DSA and the 'Create the Future Transformation Program'—aiming for $300 million in savings—position the company for long-term margin expansion.
Tickers: $CRL
Topics: backlog eps organic growth revenue segment performance